downgraded by the 'lumping' approach toward treatment decisions, which potentially devalues the role of tissue biopsy.
We therefore need to be careful not to fall into the downsides of the 'lumping' approach. It is laudable to have pragmatic approaches both clinically and in investigational trials to facilitate patients with a range of ILDs having access to new treatments that have disease-modifying potential, but we must redouble efforts to discover better biomarkers of the range of interstitial lung diseases (not just IPF) and, particularly, biomarkers (radiological, blood, lavage, genetic, even exhaled breath perhaps) that will aid in better understanding disease pathogenesis, open up potential new therapeutic pathways and, of course, to better inform discussions on prognosis with patients and optimise treatment decisions. Two papers in this issue emphasise the need for, and some of the work being done on new biomarker approaches [6, 7] . The journey in ILD is only beginning!
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